Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1887
http://purl.obolibrary.org/obo/NCIT_C1887
|
|---|---|
| Preferred Name | Epratuzumab |
| Definitions |
A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC).
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC). |
|---|---|
| label | Epratuzumab
|
| prefLabel | Epratuzumab
|
| Legacy Concept Name | Epratuzumab
|
| in_subset |
See more
See less
|
| Preferred_Name | Epratuzumab
|
| Is_Value_For_GDC_Property | |
| Display_Name | Epratuzumab
|
| Maps_To | Epratuzumab
|
| PDQ_Open_Trial_Search_ID | 42234
|
| Has_Target | |
| UMLS_CUI | C1120776
|
| FDA_UNII_Code | 3062P60MH9
|
| prefixIRI | NCIT:C1887
|
| Accepted_Therapeutic_Use_For | Systemic lupus erythematosus
|
| NCI_Drug_Dictionary_ID | 42234
|
| Contributing_Source |
CTRP
FDA
|
| subClassOf | |
| code | C1887
|
| type | |
| NSC Number | 716711
|
| PDQ_Closed_Trial_Search_ID | 42234
|
| Semantic_Type |
Amino Acid, Peptide, or Protein
Pharmacologic Substance
Immunologic Factor
|
| CAS_Registry | 205923-57-5
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |